Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 5/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.36 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20128631 | 1.00 | CRBN (0.51) | CRBNDDB1KMT2AHTR2AHTR2C | |
| SCHEMBL20128632 | 1.00 | CRBN (0.51) | CRBNDDB1KMT2AHTR2AHTR2C | |
| SCHEMBL29312174 | 0.88 | CRBN (0.50) | CRBNDDB1HTR2AHTR2CHTR2B | |
| SCHEMBL29312172 | 0.88 | CRBN (0.50) | CRBNDDB1HTR2AHTR2CHTR2B | |
| SCHEMBL25876256 | 0.86 | CRBN (0.43) | CRBNDDB1KMT2AHTR2AHTR2C | |
| SCHEMBL18179946 | 0.86 | KMT2A (0.41) | CRBNDDB1KMT2AHTR2AHTR2C | |
| SCHEMBL23250094 | 0.83 | CRBN (0.50) | CRBNDDB1HTR2B | |
| SCHEMBL27309787 | 0.83 | CRBN (0.43) | CRBNDDB1KMT2AHTR2AHTR2C | |
| SCHEMBL26188534 | 0.83 | CRBN (0.43) | CRBNDDB1KMT2AHTR2AHTR2C | |
| SCHEMBL27309802 | 0.83 | CRBN (0.43) | CRBNDDB1KMT2AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8092092-A | — | — | None | — | — | JP | disclosed |
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20220144809-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-05-12 | — | — | US | disclosed |
| WO-2022098544-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022087125-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN | ARVINAS OPERATIONS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-8143283-B1 | Methods for treating blood-born tumors with thalidomide | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-7723361-B2 | Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide | CELGENE CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-6500845-B1 | ACTIVATING CYTOKINE RELEASE USING IMMUNOSUPPRESSANTS SUCH AS 2-(3-METHYL-2-OXO-PIPERIDIN-3-YL)-BENZO(D)ISOSELENAZOL-3-ONE, RACEMIC MIXTURES OR ISOMERS HAVING DIMENSIONAL STABILITY, PREPARED IN THE PRESENCE OF REDUCING AGENT | GRUENENTHAL GMBH (DE) | 2002-12-31 | — | — | US | disclosed |
| JP-H0892092-A | USE OF LACTAM COMPOUND AS PHARMACEUTICALLY ACTIVE SUBSTANCE | GRUENENTHAL GMBH | 1996-04-09 | — | — | JP | disclosed |
| EP-0688771-A1 | Use of lactam compounds as pharmaceutical agents | Grünenthal GmbH (DE) | 1995-12-27 | — | — | EP | disclosed |
| JP-H00892092-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | ITK, IKZF2, PBK | CRBN 360/4885DDB1 2437/4885KMT2A 1074/4885 |
| US-20220144809-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USE | AR, ADRM1, CRBN | CRBN 3/4885DDB1 409/4885KMT2A 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.